CompletedNot Applicable

Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection

United States24 participantsStarted 2018-05-01

Plain-language summary

The goal is to evaluate the benefit of adding bezlotoxumab to repeat fecal microbiota transplantation (FMT) in patients with recurrent Clostridioides difficile infections after failure of FMT alone.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed consent.
✓. Diagnosis of recurrent C. difficile infection based on symptoms and laboratory confirmation.
✓. Failure of standard antibiotic therapies prior to the initial FMT

Exclusion criteria

✕. Pregnancy.
✕. Class III or above heart failure.

What they're measuring

Clinical failure

Timeframe: 90 days

Trial details

NCT IDNCT06669936

SponsorAlexander Khoruts

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-01

View on ClinicalTrials.gov More Recurrent C. Difficile Infection trials